CLVLF (Clinuvel Pharmaceuticals) Buildings And Improvements: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLVLF Clinuvel Pharmaceuticals Ltd CLVLF
85 GF Score
Price $5.89
GF Value $9.34
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals Buildings And Improvements?

Clinuvel Pharmaceuticals CLVLF -0.51% 85 Buildings And Improvements is $0.00 Mil as of Jun. 2026. GuruFocus rates CLVLF with a GF Score™ of 85/100 and a GF Value™ of $9.34 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Clinuvel Pharmaceuticals Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for Clinuvel Pharmaceuticals's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinuvel Pharmaceuticals Buildings And Improvements Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Buildings And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Clinuvel Pharmaceuticals Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CLVLF
85GF Score
Clinuvel Pharmaceuticals Ltd CLVLF
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clinuvel Pharmaceuticals Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of $0.00 Mil mean?
Clinuvel Pharmaceuticals (CLVLF) has a Buildings And Improvements of $0.00 Mil as of Jun. 2026. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Clinuvel Pharmaceuticals and its competitors.
Is Clinuvel Pharmaceuticals' Buildings And Improvements too high?
Clinuvel Pharmaceuticals' current Buildings And Improvements is $0.00 Mil. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Buildings And Improvements compare to VRTX and REGN?
Clinuvel Pharmaceuticals' Buildings And Improvements of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Biotechnology company?
A good Buildings And Improvements depends on the Biotechnology industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current Buildings And Improvements is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CLVLF) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.34, compared to a current price of $5.89 — trading 36.9% below its estimated fair value. The current Buildings And Improvements is $0.00 Mil. Clinuvel Pharmaceuticals' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CLVLF), the current Buildings And Improvements is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinuvel Pharmaceuticals (CLVLF) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of $5.89 is trading 36.9% below its estimated GF Value™ of $9.34. GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for CLVLF:

  • Buildings And Improvements: $0.00 Mil
  • GF Value™: $9.34 vs. price of $5.89 (36.9% below fair value)
  • GF Score™: 85/100 with 3 warning signs

No single metric tells the full story. See the CLVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
85GF Score

Get the complete analysis for CLVLF

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.89
Price
$9.34
GF Value